GeneDx Holdings (WGS) Could Be 24% Undervalued As It Expands Genome Sequencing

GeneDx Holdings (WGS) has put long read whole genome sequencing and a slate of 27 scientific abstracts in the spotlight, a mix of product expansion and research activity that sharpens the focus on its genomics platform.

Recent trading shows how quickly sentiment around GeneDx Holdings can swing. After a sharp 22.99% 7‑day share price return, the stock has given back some ground with a 1‑day share price move that declined 2.76% to US$69.06. The year to date share price return is down 47.80% and the 1‑year total shareholder return has fallen 49.56%, despite a very large 3‑year total shareholder return that still reflects earlier gains. As a result, momentum appears short term positive but fragile as the market reassesses the long‑term impact of the lrWGS rollout and the ASHG research push.

Scan beyond GeneDx Holdings and size up other genomics and AI-driven healthcare opportunities already filtered in our 34 healthcare AI stocks that could be next in line for heightened attention.

GeneDx Holdings now couples a growing genomics toolkit with a share price that has swung hard in both directions this year. The next step is simple: Does that mix translate into a fair valuation today?

Most Popular Narrative: 24% Undervalued

On the most followed view, GeneDx Holdings screens as undervalued, with an implied fair value of about $90.44 against the latest close at $69.06. That gap rests on a detailed story about how pediatric genomics, data scale, and AI tools could reshape the business over time.

Ongoing development and enrichment of GeneDx's comprehensive rare disease genomic database strengthens product differentiation, enables premium pricing, and creates high barriers to entry, supporting sustained top-line growth and long-term profitability as data network effects compound.

See why 26 investors see GeneDx Holdings as 24% undervalued.

The narrative uses a 7.24% discount rate to bring those future cash flows and earnings back to today, which is a relatively moderate hurdle for a genomics testing specialist that is still loss making. It ties that to expectations that earnings move from a loss of $106.4 million today to a profit of $29.2 million by around 2029, with margins shifting from negative territory into positive single digits.

To line up with that fair value, you would need to be comfortable with revenue reaching $795.6 million by 2029 and the stock trading on a P/E of 122.4x those future earnings, compared with a current loss and a sector multiple of 25.2x cited in the narrative. The implied valuation also leans on a forecast that earnings grow 72.67% per year over the next few years and that the share count increases around 3.18% annually, which affects per share outcomes.

Analysts referenced in the narrative cluster around a price target range of $74 to $103, which brackets the $90.44 fair value marker. That spread captures both the potential of larger pediatric and rare disease markets and risks such as reimbursement pressure, higher operating costs from expansion, and continued volatility after a 1 year total shareholder return that has fallen 49.56% despite a very large 3 year gain.

Result: Fair Value of $90.44 (UNDERVALUED)

Still, that story can unravel quickly if reimbursement policies tighten or if competing genetic testing platforms blunt GeneDx Holdings pricing power and slow new test adoption.

Find out about the key risks to this GeneDx Holdings narrative.

Another View: What Multiples Say About GeneDx Holdings

That 24% undervaluation story leans heavily on future cash flows and earnings. Yet on today’s revenue, GeneDx Holdings trades on a P/S of 4.5x, compared with 1.4x for the wider US Healthcare sector and 0.9x for peers, and even above its own fair ratio of 4.2x. For investors, the puzzle is simple: if growth or margins stumble, does the share price move toward that lower fair ratio instead?

For a closer look at how current trading levels stack up against these benchmarks, including what the fair ratio implies for valuation risk, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Sentiment around GeneDx Holdings is clearly mixed, with sharp swings, optimistic forecasts, and clear risks sitting side by side. If you want to move fast and base your stance on more than a headline narrative, take a moment to weigh the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond GeneDx Holdings?

Do not stop with a single stock when you can scan a wider field of opportunities using the Simply Wall St screener tools tailored to different goals.

• Target potential mispricing by focusing on companies that combine quality fundamentals with attractive entry points through the 33 high quality undervalued stocks.
• Prioritize resilience and sleep-better-at-night holdings by screening for businesses with strong finances using the list of solid balance sheet and fundamentals (24 results).
• Get ahead of the crowd by zeroing in on lesser-known opportunities with robust metrics through the 19 high quality undiscovered gems.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com